So­sei Hep­tares part­ners with a UK-based can­cer re­search or­ga­ni­za­tion to bring its drug to tri­al

Can­cer re­search has been a fo­cus for So­sei Hep­tares for sev­er­al years, and their lat­est deal hopes to progress one of their new­er ther­a­pies.

On Fri­day, the Japan­ese com­pa­ny inked a deal with Can­cer Re­search UK to bring one of its can­cer drug can­di­dates in­to the clin­ic. Ac­cord­ing to So­sei, the agree­ment will have Can­cer Re­search UK run a Phase I/IIa tri­al of So­sei’s can­cer can­di­date HTL00397322, an EP4 an­tag­o­nist. The can­di­date will be eval­u­at­ed as both a com­bi­na­tion ther­a­py and a monother­a­py. While no ex­act fi­nan­cial de­tails were giv­en, So­sei will still hold the pro­gram’s li­cense af­ter the study reads out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER